Skip to main content

Table 4 Comparison of radiographic and laboratory results between controls, improved and non-improved cases

From: Effect of sustained virological response after direct-acting antivirals on liver fibrosis in patients with chronic HCV infection

 

Control arm n=150

Non-improved cases n=880

Improved cases n=350

Test of significance

Test of sig.

Age/years

58.33±8.16

57.14±6.88

53.43±9.33

F=3.47

P=0.034*

P1=0.579

P2=0.041*

P3=0.017*

Sex

 Male

60 (40.0)

340 (38.6)

210 (60.0)

χ2=4.75

p1=0.92

p2=0.19

p3=0.032*

 Female

90 (60.0)

540 (61.4)

140 (40.0)

P=0.093

DM

30 (20.0)

310 (35.2)

40 (11.4)

MC P=0.023*

p1=0.246

p2=0.423

p3=0.008*

Hypertension

30 (20.0)

130 (14.8)

30 (8.6)

MC P=0.506

p1=0.699

p2=0.348

p3=0.356

Associated comorbidities

 −VE

20 (13.3)

80 (9.1)

20 (5.7)

MC P=0.665

p1=0.608

 +VE

130 (86.7)

800 (90.9)

330 (94.3)

p2=0.574

p3=0.723

Spleen US

 1

13.57±3.19

13.63±2.39

12.37±1.61

F=3.74, P=0.026*

p1=0.92, p2=0.09, p3=0.008*

 2

13.03±2.75

13.40±2.33

12.09±1.50

F=4.45, P=0.013*

p1=0.55, p2=0.16, p3=0.003*

 3

12.75±2.14

13.21±1.31

11.91±1.31

F=5.74, P=0.004*

p1=0.41, p2=0.17, p3=0.001*

Portal vein US

 1

12.40±2.92

12.81±2.44

10.40±1.75

F=13.29, P<0.001*

p1=0.54, p2=0.006*, p3<0.001*

 2

12.13±2.79

12.58±2.41

10.09±1.46

F=15.42, P=0.001*

p1=0.48, p2=0.004*, p3=0.001*

 3

11.50±2.28

12.35±2.42

9.89±1.25

F=16.1, P=0.001*

p1=0.17, p2=0.02*, p3=0.001*

ALT

 1

32 (15–88)

24.5 (6–60)

34 (2–78)

KW, P=0.001*

p1=01*, p2=0.82, p3<0.001*

 2

28 (15–59)

25 (10–128)

28 (16–46)

KW, P=0.23

p1=0.17, p2=0.65, p3=0.20

 3

28 (18–43)

24 (8–86)

26 (10–43)

KW, P=0.09

p1=0.05, p2=0.22, p3=0.25

 AST

 1

38 (17–94)

34 (11–85)

38 (19–71)

KW, P=0.04*

p1=0.14, p2=0.92, p3=0.02*

 2

32 (17–79)

28 (11–92)

26 (13–62)

KW, P=0.057

p1=0.27, p2=0.025*, p3=0.07

 3

28.5 (20–45)

28.5 (7–96)

23 (14–45)

KW, P=0.003*

p1=0.61, p2=0.024*, p3=0.001*

Platelet

 1

147 (57–259)

126.5 (33–256)

196 (60–343)

KW, P=0.001*

p1=0.47, p2=0.07, p3=0.001*

 2

154 (61–355)

138.5 (30–344)

187 (72–374)

KW, P=0.001*

p1=0.12, p2=0.53, p3<0.001*

 3

138.5 (30–344)

134 (37–259)

184 (60–333)

KW, P=0.001*

p1=0.24, p2=0.19, p3<0.001*

Hb

 1

13.45±1.19

12.8±1.58

13.11±1.27

F=1.08, P=0.342

p1=.17, p2=0.46, p3=0.44

 2

13.20±0.95

13.05±1.40

13.20±1.31

F=0.21, P=0.81

p1=0.682, p2=0.99, p3=0.563

 3

12.79±0.79

13.15±1.19

13.29±1.22

F=0.92, P=0.40

p1=0.286, p2=0.17, p3=0.54

WBCS

 1

7.62±2.14

5.85±2.35

6.61±2.61

F=4.06, P=0.019*

p1=0.009*, p2=0.17, p3=0.11

 2

6.83±2.05

5.78±1.94

6.08±2.32

F=1.74, P=0.179

p1=0.07, p2=0.24, p3=0.47

 3

6.04±1.39

5.81±1.72

6.03±2.06

F=0.232, P=0.793

p1=0.66, p2=0.98, p3=0.55

Bilirubin

 1

0.887±0.43

0.931±0.441

0.902±0.34

F=0.11, P=0.896

p1=0.70, p2=0.90, p3=0.73

 2

0.931±0.44

0.902±0.34

1.05±1.0

F=0.59, P=0.55

p1=0.50, p2=0.29, p3=0.48

 3

0.96±0.45

1.04±0.61

0.860±0.21

F=1.53, P=0.22

p1=0.61, p2=0.52, p3=0.08

Albumin

 1

3.93±0.53

4.13±0.39

4.22±0.37

F=2.54, P=0.082

p1=0.08, p2=0.03*, p3=0.31

 2

4.19±0.48

4.12±0.50

3.99±0.43

F=1.24, P=0.29

p1=0.59, p2=0.18, p3=0.18

 3

4.09±0.33

4.03±0.41

4.07±0.26

F=0.198, P=0.82

p1=0.62, p2=0.88, p3=0.63

EGD1

N=10

N=160

N=10

  

 OVs

0 (0.0)

50 (31.2)

0 (0.0)

MC P=0.334

p1=0.678

p2=0.157

p3=0.175

 PHG

0 (0.0)

20 (12.5)

10 (100)

 Both

10 (100)

60 (37.5)

0 (0.0)

 Free

0 (0.0)

30 (18.8)

0 (0.0)

EGD2

N=20

N=70

   

 OVs

0 (0.0)

10 (14.3)

0

MC P=0.133

p1=0.133

p2=..

p3=…

 PHG

10 (50.0)

60 (85.7)

0

 Both

10 (50.0)

0 (0.0)

0

EGD3

 PHG

20 (100.0)

40 (100.0)

0 (0.0)